AAIC 2019, Los Angeles, US

17/07/2019: Gill Farrar (GE) “The Added Value of Quantitative Amyloid PET in Determining Alzheimer’s Disease (AD) Dementia Risk: The AMYPAD Prognostic and Natural History Study”

This project has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Acknowledgements, Legal Notice and Privacy Policy